An overview of resistance to Human epidermal growth factor receptor 2(Her2)targeted therapies in breast cancer  

作　　者：Ahmed M.Elshazly David A.Gewirtz 

机构地区：[1]Department of Pharmacology and Toxicology,Faculty of Pharmacy,Kafrelsheikh University,Kafrelsheikh 33516,Egypt. [2]Department of Pharmacology and Toxicology,Virginia Commonwealth University,Richmond,VA 23298,USA.

出　　处：《Cancer Drug Resistance》2022年第2期472-486,共15页癌症耐药（英文）

摘　　要：Breast cancer(BC)is the second most common cause of cancer-related deaths and the most frequently diagnosed cancer in females.Among breast cancer types,HER2-positive breast cancer occurs in nearly 20%of human breast cancers and is associated with increased aggressiveness,poor prognosis,and shortened overall survival.HER2+breast cancer is currently managed with multidisciplinary treatment strategies including surgery,radiation,chemotherapy,and targeted therapy.Drug resistance remains a continuing challenge,especially to targeted therapy utilizing monoclonal antibodies and tyrosine kinase inhibitors.This review discusses some of the recent molecular mechanisms that are involved in the development of resistance to Her2-targeted therapies including the PI3K/Akt/mTOR pathway,IGF-IR,Src,c-MET,the PP2A family,CD36,p27^(kip1),and miRNAs.

关 键 词：HER2+ Targeted therapy resistance IGF-IR SRC C-MET PP2A CD36 miRNA 

分 类 号：R73[医药卫生—肿瘤]